EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Latency Reversing Agents and the Road to an HIV Cure

Louis Tioka, Rafael Ceña Diez, Anders Sönnerborg iD, Maarten A A van de Klundert iD

Pathogens · 27.02.2025 · 14 (3) · 232

DOI: 10.3390/pathogens14030232 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 27.02.2025. Verfasst von Louis Tioka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Erlangen-Nürnberg, Friedrich-Alexander-Universität, 91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Virus Latency, HIV Infections, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV-1 infection cannot be cured due to the presence of HIV-1 latently infected cells. These cells do not produce the virus, but they can resume virus production at any time in the absence of antiretroviral therapy. Therefore, people living with HIV (PLWH) need to take lifelong therapy. Strategies have been coined to eradicate the viral reservoir by reactivating HIV-1 latently infected cells and subsequently killing them. Various latency reversing agents (LRAs) that can reactivate HIV-1 in vitro and ex vivo have been identified. The most potent LRAs also strongly activate T cells and therefore cannot be applied in vivo. Many LRAs that reactivate HIV in the absence of general T cell activation have been identified and have been tested in clinical trials. Although some LRAs could reduce the reservoir size in clinical trials, so far, they have failed to eradicate the reservoir. More recently, immune modulators have been applied in PLWH, and the first results seem to indicate that these may reduce the reservoir and possibly improve immunological control after therapy interruption. Potentially, combinations of LRAs and immune modulators could reduce the reservoir size, and in the future, immunological control may enable PLWH to live without developing HIV-related disease in the absence of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus LatencyHIV InfectionsHIV-1Anti-HIV AgentsVirus ActivationHumans

Stichwörter der Autor:innen

HIV cureHIV-1kick and killlatencylatency reversallatency reversing agentsviral reservoir

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Erlangen-Nürnberg, Friedrich-Alexander-Universität, 91054 Erlangen, Germany.
  • Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, 17177 Stockholm, Sweden.
  • Department of Infectious Diseases, Karolinska University Hospital, 17177 Stockholm, Sweden.
  • Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.

ORCID-Profile: Anders Sönnerborg, Maarten A A van de Klundert

Zitieren

APA

Tioka, L., Diez, R. C., Sönnerborg, A., & van de Klundert, M. A. A. (2025). Latency Reversing Agents and the Road to an HIV Cure. Pathogens, 14(3), 232. https://doi.org/10.3390/pathogens14030232

Vancouver

Tioka L, Diez RC, Sönnerborg A, van de Klundert MAA. Latency Reversing Agents and the Road to an HIV Cure. Pathogens. 2025;14(3):232. doi:10.3390/pathogens14030232

BibTeX
@article{Tioka2025,
  author = {Tioka, Louis and Diez, Rafael Ceña and Sönnerborg, Anders and van de Klundert, Maarten A A},
  title = {Latency Reversing Agents and the Road to an HIV Cure},
  journal = {Pathogens},
  year = {2025},
  volume = {14},
  number = {3},
  pages = {232},
  doi = {10.3390/pathogens14030232}
}
Kostenlos starten →